Study finds Pfizer’s antiviral has little or even zero benefit for younger adults, and WHO says BA.5 omicron subvariant accounted for 74% of cases in latest week

Study finds Pfizer's antiviral has little or even zero benefit for younger adults, and WHO says BA.5 omicron subvariant accounted for 74% of cases in latest week

Pfizer’s COVID antiviral Paxlovid appears to have little or no benefit for younger adults, although it still reduces the risk of hospitalization or death in seniors, according to a new Israeli study. Data from the 109,000-patient study may renew questions about the US government’s use of Paxlovid, which has become the go-to treatment for COVID-19 … Read more

Polio and the monkeypox outbreak demonstrate a ‘heightened focus’ on viruses

Polio and the monkeypox outbreak demonstrate a 'heightened focus' on viruses

Two-plus years of COVID-19, and people are thinking differently about viruses. The US this month declared monkeypox a public health emergency, and people at high risk of getting the virus — particularly men who have sex with men — are lining up in city streets to get vaccinated. An avian flu outbreak that pushed egg … Read more

Ivermectin among generic drugs that failed to help COVID-19 patients avoid hospitalization, large study shows

Ivermectin among generic drugs that failed to help COVID-19 patients avoid hospitalization, large study shows

A new study found three generic drugs — fluvoxamine, which is often prescribed to treat depression, the controversial antimalarial ivermectin, and the diabetes pill metformin — failed to prevent the kind of severe COVID-19 that leads to an emergency-room visit or hospitalization. The research, published Wednesday in The New England Journal of Medicine, examined whether … Read more